Verapamil in Prophylaxis of Paroxysmal Atrioventricular Nodal Reentrant Tachycardia

We examined by electrophysiologic study and clinical follow-up the use of verapamil as a prophylactic agent in 13 patients with refractory paroxysmal supraventricular tachycardia due to atrioventricular (AV) node reentry. Electrophysiologic variables and initiation and maintenance of AV nodal reentr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiovascular pharmacology 1980-09, Vol.2 (5), p.473-486
Hauptverfasser: Tonkin, Andrew M, Aylward, Philip E, Joel, Sandra E, Heddle, William F
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 486
container_issue 5
container_start_page 473
container_title Journal of cardiovascular pharmacology
container_volume 2
creator Tonkin, Andrew M
Aylward, Philip E
Joel, Sandra E
Heddle, William F
description We examined by electrophysiologic study and clinical follow-up the use of verapamil as a prophylactic agent in 13 patients with refractory paroxysmal supraventricular tachycardia due to atrioventricular (AV) node reentry. Electrophysiologic variables and initiation and maintenance of AV nodal reentry were studied by programmed electrical stimulation. Observations were made before and after intravenous administration of verapamil, 0.15 mg/kg. Twelve of the 13 patients had previously not been controlled by other antiarrhythmic agents. Before verapamil, AV nodal reentry was induced in all 13 patients. Verapamil increased AV nodal transmission time (AH interval), as well as the effective and functional refractory periods of the AV node. Reentry could not be initiated in 5 of the 13 patients after verapamil and was nonsustained in a further 3. The echo zone for atrial premature beats which initiated tachycardia decreased in 2 of the remaining 5 patients. The rate of tachycardia was also significantly decreased. Over a mean follow-up period of 16 months, 11 of the 13 patients had definite symptomatic improvement, with decrease in frequency, duration, and/or associated symptoms of their arrhythmia. Only 1 patient had side effects which necessitated withdrawal of the drug. It was concluded that verapamil is a useful agent in the management of such patients.
doi_str_mv 10.1097/00005344-198009000-00001
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75250010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75250010</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4051-e0fb5f7952a4082fd7a8b74828f383a2f2c4530164aa1348fc2b3c8c3f770e043</originalsourceid><addsrcrecordid>eNp1UctOAzEMjBColMcnIO2J20KeTfaIEC8JQQWFa-SmibqQbUqyS9u_J6WlN3wZeTy25TFCBcEXBFfyEucQjPOSVArjKmflmiJ7qE8EYyXHlO2jPiYDXFLOB4foKKWPLOBCDnqoNyBCVpz30eu7jTCHpvZFPSuGMcynKw_LOhXBFUOIYblKDfjiqo11-LazDKbzEIunMMn0i11TMGuLEZjpykCc1HCCDhz4ZE-3eIzebm9G1_fl4_Pdw_XVY2k4FqS02I2Fk5WgwLGibiJBjSVXVDmmGFBHDRcsn8ABCOPKGTpmRhnmpMQWc3aMzjdz5zF8dTa1uqmTsd7DzIYuaSmoyCfjLFQboYkhpWidnse6gbjSBOu1n_rPT73z85ciufVsu6MbN3aya9wamOt8U18E39qYPn23sFFPLfh2qv97E_sBGkuAEg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75250010</pqid></control><display><type>article</type><title>Verapamil in Prophylaxis of Paroxysmal Atrioventricular Nodal Reentrant Tachycardia</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Tonkin, Andrew M ; Aylward, Philip E ; Joel, Sandra E ; Heddle, William F</creator><creatorcontrib>Tonkin, Andrew M ; Aylward, Philip E ; Joel, Sandra E ; Heddle, William F</creatorcontrib><description>We examined by electrophysiologic study and clinical follow-up the use of verapamil as a prophylactic agent in 13 patients with refractory paroxysmal supraventricular tachycardia due to atrioventricular (AV) node reentry. Electrophysiologic variables and initiation and maintenance of AV nodal reentry were studied by programmed electrical stimulation. Observations were made before and after intravenous administration of verapamil, 0.15 mg/kg. Twelve of the 13 patients had previously not been controlled by other antiarrhythmic agents. Before verapamil, AV nodal reentry was induced in all 13 patients. Verapamil increased AV nodal transmission time (AH interval), as well as the effective and functional refractory periods of the AV node. Reentry could not be initiated in 5 of the 13 patients after verapamil and was nonsustained in a further 3. The echo zone for atrial premature beats which initiated tachycardia decreased in 2 of the remaining 5 patients. The rate of tachycardia was also significantly decreased. Over a mean follow-up period of 16 months, 11 of the 13 patients had definite symptomatic improvement, with decrease in frequency, duration, and/or associated symptoms of their arrhythmia. Only 1 patient had side effects which necessitated withdrawal of the drug. It was concluded that verapamil is a useful agent in the management of such patients.</description><identifier>ISSN: 0160-2446</identifier><identifier>EISSN: 1533-4023</identifier><identifier>DOI: 10.1097/00005344-198009000-00001</identifier><identifier>PMID: 6157944</identifier><language>eng</language><publisher>United States: Lippincott-Raven Publishers</publisher><subject>Adult ; Aged ; Atrioventricular Node - physiopathology ; Electroencephalography ; Electrophysiology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Tachycardia, Paroxysmal - physiopathology ; Tachycardia, Paroxysmal - prevention &amp; control ; Verapamil - therapeutic use</subject><ispartof>Journal of cardiovascular pharmacology, 1980-09, Vol.2 (5), p.473-486</ispartof><rights>Lippincott-Raven Publishers.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4051-e0fb5f7952a4082fd7a8b74828f383a2f2c4530164aa1348fc2b3c8c3f770e043</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;NEWS=n&amp;CSC=Y&amp;PAGE=fulltext&amp;D=ovft&amp;AN=00005344-198009000-00001$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,776,780,4595,27901,27902,65206</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6157944$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tonkin, Andrew M</creatorcontrib><creatorcontrib>Aylward, Philip E</creatorcontrib><creatorcontrib>Joel, Sandra E</creatorcontrib><creatorcontrib>Heddle, William F</creatorcontrib><title>Verapamil in Prophylaxis of Paroxysmal Atrioventricular Nodal Reentrant Tachycardia</title><title>Journal of cardiovascular pharmacology</title><addtitle>J Cardiovasc Pharmacol</addtitle><description>We examined by electrophysiologic study and clinical follow-up the use of verapamil as a prophylactic agent in 13 patients with refractory paroxysmal supraventricular tachycardia due to atrioventricular (AV) node reentry. Electrophysiologic variables and initiation and maintenance of AV nodal reentry were studied by programmed electrical stimulation. Observations were made before and after intravenous administration of verapamil, 0.15 mg/kg. Twelve of the 13 patients had previously not been controlled by other antiarrhythmic agents. Before verapamil, AV nodal reentry was induced in all 13 patients. Verapamil increased AV nodal transmission time (AH interval), as well as the effective and functional refractory periods of the AV node. Reentry could not be initiated in 5 of the 13 patients after verapamil and was nonsustained in a further 3. The echo zone for atrial premature beats which initiated tachycardia decreased in 2 of the remaining 5 patients. The rate of tachycardia was also significantly decreased. Over a mean follow-up period of 16 months, 11 of the 13 patients had definite symptomatic improvement, with decrease in frequency, duration, and/or associated symptoms of their arrhythmia. Only 1 patient had side effects which necessitated withdrawal of the drug. It was concluded that verapamil is a useful agent in the management of such patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Atrioventricular Node - physiopathology</subject><subject>Electroencephalography</subject><subject>Electrophysiology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Tachycardia, Paroxysmal - physiopathology</subject><subject>Tachycardia, Paroxysmal - prevention &amp; control</subject><subject>Verapamil - therapeutic use</subject><issn>0160-2446</issn><issn>1533-4023</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1980</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UctOAzEMjBColMcnIO2J20KeTfaIEC8JQQWFa-SmibqQbUqyS9u_J6WlN3wZeTy25TFCBcEXBFfyEucQjPOSVArjKmflmiJ7qE8EYyXHlO2jPiYDXFLOB4foKKWPLOBCDnqoNyBCVpz30eu7jTCHpvZFPSuGMcynKw_LOhXBFUOIYblKDfjiqo11-LazDKbzEIunMMn0i11TMGuLEZjpykCc1HCCDhz4ZE-3eIzebm9G1_fl4_Pdw_XVY2k4FqS02I2Fk5WgwLGibiJBjSVXVDmmGFBHDRcsn8ABCOPKGTpmRhnmpMQWc3aMzjdz5zF8dTa1uqmTsd7DzIYuaSmoyCfjLFQboYkhpWidnse6gbjSBOu1n_rPT73z85ciufVsu6MbN3aya9wamOt8U18E39qYPn23sFFPLfh2qv97E_sBGkuAEg</recordid><startdate>198009</startdate><enddate>198009</enddate><creator>Tonkin, Andrew M</creator><creator>Aylward, Philip E</creator><creator>Joel, Sandra E</creator><creator>Heddle, William F</creator><general>Lippincott-Raven Publishers</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198009</creationdate><title>Verapamil in Prophylaxis of Paroxysmal Atrioventricular Nodal Reentrant Tachycardia</title><author>Tonkin, Andrew M ; Aylward, Philip E ; Joel, Sandra E ; Heddle, William F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4051-e0fb5f7952a4082fd7a8b74828f383a2f2c4530164aa1348fc2b3c8c3f770e043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1980</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Atrioventricular Node - physiopathology</topic><topic>Electroencephalography</topic><topic>Electrophysiology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Tachycardia, Paroxysmal - physiopathology</topic><topic>Tachycardia, Paroxysmal - prevention &amp; control</topic><topic>Verapamil - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tonkin, Andrew M</creatorcontrib><creatorcontrib>Aylward, Philip E</creatorcontrib><creatorcontrib>Joel, Sandra E</creatorcontrib><creatorcontrib>Heddle, William F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiovascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tonkin, Andrew M</au><au>Aylward, Philip E</au><au>Joel, Sandra E</au><au>Heddle, William F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Verapamil in Prophylaxis of Paroxysmal Atrioventricular Nodal Reentrant Tachycardia</atitle><jtitle>Journal of cardiovascular pharmacology</jtitle><addtitle>J Cardiovasc Pharmacol</addtitle><date>1980-09</date><risdate>1980</risdate><volume>2</volume><issue>5</issue><spage>473</spage><epage>486</epage><pages>473-486</pages><issn>0160-2446</issn><eissn>1533-4023</eissn><abstract>We examined by electrophysiologic study and clinical follow-up the use of verapamil as a prophylactic agent in 13 patients with refractory paroxysmal supraventricular tachycardia due to atrioventricular (AV) node reentry. Electrophysiologic variables and initiation and maintenance of AV nodal reentry were studied by programmed electrical stimulation. Observations were made before and after intravenous administration of verapamil, 0.15 mg/kg. Twelve of the 13 patients had previously not been controlled by other antiarrhythmic agents. Before verapamil, AV nodal reentry was induced in all 13 patients. Verapamil increased AV nodal transmission time (AH interval), as well as the effective and functional refractory periods of the AV node. Reentry could not be initiated in 5 of the 13 patients after verapamil and was nonsustained in a further 3. The echo zone for atrial premature beats which initiated tachycardia decreased in 2 of the remaining 5 patients. The rate of tachycardia was also significantly decreased. Over a mean follow-up period of 16 months, 11 of the 13 patients had definite symptomatic improvement, with decrease in frequency, duration, and/or associated symptoms of their arrhythmia. Only 1 patient had side effects which necessitated withdrawal of the drug. It was concluded that verapamil is a useful agent in the management of such patients.</abstract><cop>United States</cop><pub>Lippincott-Raven Publishers</pub><pmid>6157944</pmid><doi>10.1097/00005344-198009000-00001</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0160-2446
ispartof Journal of cardiovascular pharmacology, 1980-09, Vol.2 (5), p.473-486
issn 0160-2446
1533-4023
language eng
recordid cdi_proquest_miscellaneous_75250010
source MEDLINE; Journals@Ovid LWW Legacy Archive; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete
subjects Adult
Aged
Atrioventricular Node - physiopathology
Electroencephalography
Electrophysiology
Female
Follow-Up Studies
Humans
Male
Middle Aged
Tachycardia, Paroxysmal - physiopathology
Tachycardia, Paroxysmal - prevention & control
Verapamil - therapeutic use
title Verapamil in Prophylaxis of Paroxysmal Atrioventricular Nodal Reentrant Tachycardia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A23%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Verapamil%20in%20Prophylaxis%20of%20Paroxysmal%20Atrioventricular%20Nodal%20Reentrant%20Tachycardia&rft.jtitle=Journal%20of%20cardiovascular%20pharmacology&rft.au=Tonkin,%20Andrew%20M&rft.date=1980-09&rft.volume=2&rft.issue=5&rft.spage=473&rft.epage=486&rft.pages=473-486&rft.issn=0160-2446&rft.eissn=1533-4023&rft_id=info:doi/10.1097/00005344-198009000-00001&rft_dat=%3Cproquest_cross%3E75250010%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75250010&rft_id=info:pmid/6157944&rfr_iscdi=true